Review summary
Teaching objective: Manage new paroxysmal atrial fibrillation triggered by Graves' hyperthyroidism in a fit 66-year-old: rate control with a beta-blocker and no cardioversion or antiarrhythmic while thyrotoxic, CHA2DS2-VASc and HAS-BLED scoring with a shared anticoagulation decision, methimazole pretreatment with safety monitoring, radioactive iodine as definitive treatment, recognition of the expected hypothyroidism afterwards, levothyroxine started at a cautious dose and titrated by TSH, confirmation of sustained sinus rhythm before stopping anticoagulation, on the CMID atrial fibrillation and hypothyroidism schedules with the 2023 ACC/AHA/ACCP/HRS and ATA guidelines.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| June 12, 1924 | Born in Milton, Massachusetts. | CLM-0001 |
| May 4, 1991 | Atrial fibrillation while running; admitted to hospital; ECG and cardiac ultrasound otherwise normal. | CLM-0002 |
| May 6, 1991 | Sinus rhythm restored on medication; discharged. | CLM-0003, CLM-0004 |
| May 1991 | Diagnosed with Graves' disease later the same week. | CLM-0005 |
| Later in 1991 (month not verified) | Radioactive iodine for Graves' disease; weight loss partly regained; thyroid hormone level later low, and thyroid hormone replacement begun. | CLM-0006, CLM-0007 |
| March 26, 1992 | Physical examination: thyroid function normal on Synthroid 0.15 mg a day; normal ECG. | CLM-0008 |
| November 30, 2018 | Died at 94. | CLM-0009 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | George Herbert Walker Bush was born in Milton, Massachusetts, on June 12, 1924. | confirmed | George H. W. Bush (presidential biography) supports |
| D | On May 4, 1991, he developed atrial fibrillation while running at Camp David; it presented as unusual fatigue during the run. He was flown to Bethesda Naval Hospital, where an electrocardiogram showed no abnormality except the irregular rhythm and a cardiac ultrasound showed no structural abnormality and normal heart function. Treatment began with digoxin. White House statement issued the same evening. |
confirmed | Statement by Press Secretary Fitzwater on the President's Health, May 4, 1991 supports |
| D | On May 5, 1991, the White House said he still had atrial fibrillation, with no sign of heart damage or heart attack, and that procainamide had been added to digoxin; electrical cardioversion would be considered if the rhythm did not return to normal. | confirmed | Statement by Press Secretary Fitzwater on the President's Health, May 5, 1991 (morning) supports Statement by Press Secretary Fitzwater on the President's Health, May 5, 1991 (evening) supports |
| D | His normal rhythm returned late on May 5, atrial fibrillation recurred early on May 6, and cardioversion was judged unnecessary because his response to medication was encouraging. He was discharged on May 6 and was in normal sinus rhythm later that day, on digoxin and procainamide. | confirmed | Statement by Press Secretary Fitzwater on the President's Health, May 6, 1991 (morning) supports Statement by Press Secretary Fitzwater on the President's Health, May 6, 1991 (evening) supports |
| D | Later in the same week he was diagnosed with Graves' disease. Editorial note to the May 4 statement in the Public Papers. |
confirmed | Statement by Press Secretary Fitzwater on the President's Health, May 4, 1991 supports |
| D | A physician's account published in 2016 reports a ventricular rate of 150 beats per minute on arrival at the hospital, an overactive thyroid as the explanation for the atrial fibrillation, treatment with an oral dose of radioactive iodine, a thyroid hormone level that became too low within a few months, and synthetic thyroid hormone thereafter for life. Secondary account by a physician writing for a newspaper; the exact date of the radioactive iodine treatment was not verified. |
probable | Schwartz AB. Medical Mystery: A president's love of exercise reveals an issue supports |
| D | Newsweek reported that he had regained eight of the 13 pounds he lost after doctors used radioactive iodine to control his overactive thyroid. News report; the article date was not verified. |
probable | Bush Health Mystery supports |
| D | After his physical examination on March 26, 1992, the White House reported that his thyroid function remained completely normal on Synthroid 0.15 milligrams a day, that his electrocardiogram was normal and there was no evidence of heart disease, that hip and neck x-rays showed mild degenerative osteoarthritis, and that raised pressure in his left eye was stable without signs of glaucoma. Confirms lifelong levothyroxine replacement and sinus rhythm after treatment. Later than the episode; recorded in the claims only. |
confirmed | Statements by Press Secretary Fitzwater on the President's Physical Examination, March 26, 1992 supports |
| D | He died on November 30, 2018, at the age of 94. | confirmed | George H. W. Bush (presidential biography) supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Paroxysmal atrial fibrillation, first detected four days before intake while running, triggered by hyperthyroidism; CHA2DS2-VASc 1; synthetic modern episode linked to his documented atrial fibrillation | active | confirmed | both_with_link | CLM-0002, CLM-0003, CLM-0004 |
| S | Graves' disease with hyperthyroidism; synthetic modern diagnosis linked to his documented Graves' disease | active | confirmed | both_with_link | CLM-0005, CLM-0006 |
| S | Hypothyroidism after radioactive iodine, on levothyroxine replacement | active | confirmed | both_with_link | CLM-0006, CLM-0008 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-05-08 | Thyrotropin [Units/volume] in Serum or Plasma | 0.005 mIU/L (low) Reference 0.4-4 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-05-08 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 3.6 ng/dL (high) Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 2026-05-08 | Triiodothyronine (T3) [Mass/volume] in Serum or Plasma | 280 ng/dL (high) Reference 80-200 ng/dL |
http://loinc.org · 3053-6 |
| S | 2026-05-08 | Thyrotropin receptor Ab [Units/volume] in Serum | 8.2 [IU]/L (high) Reference <=1.75 [IU]/L |
http://loinc.org · 5385-0 |
| S | 2026-05-08 | Leukocytes [#/volume] in Blood by Automated count | 6.8 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-05-08 | Neutrophils [#/volume] in Blood by Automated count | 3.9 10*3/uL Reference 1.5-7.5 10*3/uL |
http://loinc.org · 751-8 |
| S | 2026-05-08 | Hemoglobin [Mass/volume] in Blood | 14.8 g/dL Reference 13.5-17.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-05-08 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 32 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-05-08 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 mg/dL Reference 0.7-1.3 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-05-08 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 87 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-05-08 | Potassium [Moles/volume] in Serum or Plasma | 4.2 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-05-20 | Thyrotropin [Units/volume] in Serum or Plasma | 0.01 mIU/L (low) Reference 0.4-4 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-05-20 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 2.2 ng/dL (high) Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 2026-05-20 | Triiodothyronine (T3) [Mass/volume] in Serum or Plasma | 176 ng/dL Reference 80-200 ng/dL |
http://loinc.org · 3053-6 |
| S | 2026-05-20 | Neutrophils [#/volume] in Blood by Automated count | 3.5 10*3/uL Reference 1.5-7.5 10*3/uL |
http://loinc.org · 751-8 |
| S | 2026-05-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-07-17 | Thyrotropin [Units/volume] in Serum or Plasma | 5.6 mIU/L (high) Reference 0.4-4 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-07-17 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 0.6 ng/dL (low) Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 2026-07-17 | Triiodothyronine (T3) [Mass/volume] in Serum or Plasma | 78 ng/dL (low) Reference 80-200 ng/dL |
http://loinc.org · 3053-6 |
| S | 2026-09-11 | Thyrotropin [Units/volume] in Serum or Plasma | 6.4 mIU/L (high) Reference 0.4-4 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-09-11 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 0.9 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 2026-10-16 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-10-16 | Total score [Mini-Cog] | 5 | http://loinc.org · 72233-0 |
| S | 2026-10-16 | Total score [AUDIT-C] | 1 | http://loinc.org · 75626-2 |
| S | 2026-10-16 | Thyrotropin [Units/volume] in Serum or Plasma | 2.6 mIU/L Reference 0.4-4 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-10-16 | Cholesterol [Mass/volume] in Serum or Plasma | 186 mg/dL Reference <=200 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-10-16 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 mg/dL Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-10-16 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 108 mg/dL Reference <=129 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-10-16 | Triglyceride [Mass/volume] in Serum or Plasma | 100 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-10-16 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4% Reference <=5.6% |
http://loinc.org · 4548-4 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-05-08 | Body height | 188 cm | 8302-2 | S |
| 2026-05-08 | Body weight | 86 kg | 29463-7 | S |
| 2026-05-08 | Body mass index (BMI) [Ratio] | 24.3 kg/m2 | 39156-5 | S |
| 2026-05-08 | Systolic blood pressure | 142 mm[Hg] | 8480-6 | S |
| 2026-05-08 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 2026-05-08 | Heart rate | 88 /min | 8867-4 | S |
| 2026-05-08 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-05-08 | Body temperature | 37.1 Cel | 8310-5 | S |
| 2026-05-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-05-20 | Body height | 188 cm | 8302-2 | S |
| 2026-05-20 | Body weight | 86.4 kg | 29463-7 | S |
| 2026-05-20 | Body mass index (BMI) [Ratio] | 24.4 kg/m2 | 39156-5 | S |
| 2026-05-20 | Systolic blood pressure | 132 mm[Hg] | 8480-6 | S |
| 2026-05-20 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 2026-05-20 | Heart rate | 72 /min | 8867-4 | S |
| 2026-05-20 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-05-20 | Body temperature | 36.9 Cel | 8310-5 | S |
| 2026-05-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-07-17 | Body height | 188 cm | 8302-2 | S |
| 2026-07-17 | Body weight | 88.6 kg | 29463-7 | S |
| 2026-07-17 | Body mass index (BMI) [Ratio] | 25.1 kg/m2 | 39156-5 | S |
| 2026-07-17 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-07-17 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-07-17 | Heart rate | 64 /min | 8867-4 | S |
| 2026-07-17 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-07-17 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-07-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-09-11 | Body height | 188 cm | 8302-2 | S |
| 2026-09-11 | Body weight | 90.2 kg | 29463-7 | S |
| 2026-09-11 | Body mass index (BMI) [Ratio] | 25.5 kg/m2 | 39156-5 | S |
| 2026-09-11 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-09-11 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-09-11 | Heart rate | 62 /min | 8867-4 | S |
| 2026-09-11 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-09-11 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-09-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-10-16 | Body height | 188 cm | 8302-2 | S |
| 2026-10-16 | Body weight | 90.8 kg | 29463-7 | S |
| 2026-10-16 | Body mass index (BMI) [Ratio] | 25.7 kg/m2 | 39156-5 | S |
| 2026-10-16 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-10-16 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-10-16 | Heart rate | 68 /min | 8867-4 | S |
| 2026-10-16 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-16 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-10-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Never used tobacco; alcohol rarely, a glass of wine with dinner; no other drug use
- S Works full time in a demanding executive role with frequent travel; married and lives with his spouse
- S Runs about three miles four or five days a week; stopped running after the hospital stay on advice to build back gradually
- S Two to three cups of coffee a day; no energy drinks or decongestants
- S Supports: spouse, adult children, and close colleagues and friends
Functional status
- S At intake, independent in all activities but more tired than usual on runs, with some weight loss despite a good appetite
- S Back to running three miles four days a week without palpitations by the four-month review
Mental status
- S Alert, cheerful, and talkative
- S Mood good
Allergies and medications
Allergies
- S No known allergy
Medications
- S Metoprolol succinate extended-release 50 mg oral tablet, one tablet by mouth daily (started in hospital)
- S Metoprolol succinate extended-release 25 mg oral tablet, one tablet by mouth daily (taper)
- S Apixaban 5 mg oral tablet, one tablet by mouth twice daily (started in hospital)
- S Methimazole 10 mg oral tablet, two tablets (20 mg) by mouth daily
- S Levothyroxine 75 mcg oral tablet, one tablet by mouth daily before breakfast
- S Levothyroxine 100 mcg oral tablet, one tablet by mouth daily before breakfast
Procedures and immunizations
Procedures
- S Transthoracic echocardiogram in hospital: normal chamber sizes, including the left atrium, normal valves, and left ventricular ejection fraction 60 percent
- S 12-lead ECG at intake: sinus rhythm at 88 per minute, normal intervals, no ischemic change
- S Radioactive iodine (iodine-131, 15 mCi by mouth) for Graves' disease, with written radiation-safety instructions
- S 14-day ambulatory ECG patch: sinus rhythm throughout, no atrial fibrillation or flutter, rare atrial ectopic beats
- S Advance care planning conversation, about 20 minutes
Immunizations
- S 2025-10-14: High-dose influenza vaccine, 2025-2026 season
- S 2024-10-08: Pneumococcal conjugate vaccine PCV20
- S 2022-03-15: Recombinant zoster vaccine, two-dose series completed
- S 2026-10-16: High-dose influenza vaccine, 2026-2027 season
- S 2026-10-16: Tdap vaccine
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D May 4, 1991: Atrial fibrillation that began as unusual fatigue while running; hospital stay of two days, with normal ECG apart from the rhythm and a normal cardiac ultrasound; sinus rhythm restored on medication without cardioversion (CLM-0002, CLM-0003, CLM-0004)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Resting heart rate below 110 per minute without palpitations while thyrotoxic | 2026-05-20 | completed | Heart rate 72 in sinus rhythm on metoprolol two weeks after intake |
| No atrial fibrillation once no longer thyrotoxic, confirmed by ambulatory monitoring before the anticoagulation decision | 2026-09-11 | completed | Sinus rhythm throughout a 14-day ECG patch |
| TSH within 0.4 to 4.0 mIU/L on levothyroxine | 2026-10-16 | completed | TSH 6.4 on 75 mcg at the four-month review; 2.6 five weeks after the increase to 100 mcg |
| Back to running three miles several days a week without symptoms | 2026-09-11 | completed | Running three miles four days a week without palpitations |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Rate control with metoprolol succinate 50 mg daily; no antiarrhythmic drug or cardioversion while thyrotoxic, because most thyrotoxic atrial fibrillation reverts once thyroid levels are normal; taper the beta-blocker once he is no longer thyrotoxic | completed | GL-ACC-AF-2023, GL-CMID-2026, GL-ATA-HYPER-2016 |
| Stroke-risk and bleeding-risk scoring (CHA2DS2-VASc 1 for age 65 to 74; HAS-BLED 1 for age over 65) with a shared decision to continue apixaban 5 mg twice daily while thyrotoxic, then reassess once sustained sinus rhythm is confirmed after he is no longer thyrotoxic | completed | GL-ACC-AF-2023, GL-CMID-2026 |
| Methimazole 20 mg daily after a baseline blood count and liver tests, with written advice to stop it and call at once for fever, sore throat, mouth ulcers, jaundice, or dark urine; stop three days before radioactive iodine | completed | GL-ATA-HYPER-2016 |
| Endocrinology consultation to confirm Graves' disease, assess the eyes, and choose definitive treatment (radioactive iodine, long-term methimazole, or surgery) | completed | GL-ATA-HYPER-2016 |
| After radioactive iodine: free T4 and total T3 within one to two months and then every four to six weeks until stable; levothyroxine once hypothyroid, started below full replacement; TSH four to eight weeks after each dose change, at six months once stable, then yearly; target TSH 0.4 to 4.0 mIU/L | completed | GL-ATA-HYPER-2016, GL-ATA-HYPO-2014, GL-CMID-2026 |
| Atrial fibrillation monitoring at every visit (heart rate and rhythm, blood pressure, weight, symptoms, activity, alcohol, tobacco), ECG when indicated, echocardiogram at diagnosis, CHA2DS2-VASc and HAS-BLED yearly, creatinine and blood count at baseline and yearly on apixaban, and sleep apnea screening at diagnosis and yearly | completed | GL-ACC-AF-2023, GL-CMID-2026 |
| Return to running in steps once the heart rate is controlled, aiming for about 210 minutes a week of moderate to vigorous activity; limit alcohol to no more than one drink a day | completed | GL-ACC-AF-2023, GL-CMID-2026 |
Planned encounters
- 2026-05-08 — Post-hospital visit for new atrial fibrillation, with thyroid tests showing hyperthyroidism (ENC-001)
- 2026-05-20 — Two-week review on methimazole, with endocrinology consultation (ENC-002)
- 2026-07-17 — Seven-week review after radioactive iodine (ENC-003)
- 2026-09-11 — Four-month review: levothyroxine titration and anticoagulation decision (ENC-004)
- 2026-10-16 — Subsequent annual wellness visit (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Care-plan review)
- Progress note 05 — Annual Wellness Visit, Subsequent
- Endocrinology referral
- Endocrinology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Care-plan review) (XML)
- Progress note 05 — Annual Wellness Visit, Subsequent (XML)
- Endocrinology referral (XML)
- Endocrinology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | George H. W. Bush (presidential biography) | The White House (archived site) | government |
| SRC-0002 | Statement by Press Secretary Fitzwater on the President's Health, May 4, 1991 | U.S. Government Publishing Office, Public Papers of the Presidents of the United States: George H. W. Bush (1991, Book I), p. 473 | primary |
| SRC-0003 | Statement by Press Secretary Fitzwater on the President's Health, May 5, 1991 (morning) | U.S. Government Publishing Office, Public Papers of the Presidents of the United States: George H. W. Bush (1991, Book I), pp. 473-474 | primary |
| SRC-0004 | Statement by Press Secretary Fitzwater on the President's Health, May 5, 1991 (evening) | U.S. Government Publishing Office, Public Papers of the Presidents of the United States: George H. W. Bush (1991, Book I), pp. 474-475 | primary |
| SRC-0005 | Statement by Press Secretary Fitzwater on the President's Health, May 6, 1991 (morning) | U.S. Government Publishing Office, Public Papers of the Presidents of the United States: George H. W. Bush (1991, Book I), p. 475 | primary |
| SRC-0006 | Statement by Press Secretary Fitzwater on the President's Health, May 6, 1991 (evening) | U.S. Government Publishing Office, Public Papers of the Presidents of the United States: George H. W. Bush (1991, Book I), pp. 478-479 | primary |
| SRC-0007 | Statements by Press Secretary Fitzwater on the President's Physical Examination, March 26, 1992 | U.S. Government Publishing Office, Public Papers of the Presidents of the United States: George H. W. Bush (1992, Book I), p. 506 | primary |
| SRC-0008 | Schwartz AB. Medical Mystery: A president's love of exercise reveals an issue | The Philadelphia Inquirer | other |
| SRC-0009 | Bush Health Mystery | Newsweek | other |
| SRC-0010 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the anticoagulation decision at CHA2DS2-VASc 1, the methimazole pretreatment, the levothyroxine starting dose, and the deviation recorded for the late sleep apnea screen. |
| provenance review | not_started | Recent-death rule: only White House statements in the Public Papers of the Presidents, a physician's newspaper account, a news report, and the White House biography are used. No political content; no relative's health is used. |
| safe messaging review | not_started | No behavioral-health diagnosis; no sensitive claims; death recorded without detail. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.